The 22 percent-plus hit taken last week by ArQule Inc. last week signaled investor jitters on word that Stephen Hill, president and CEO, is stepping down as of March. Analysts sought to calm Wall Street, but observers hardly required long memories to recall the June 2006 case of Anadys Pharmaceuticals Inc. (BioWorld Financial Watch) Read More
